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Abstract: This study aimed to develop a carbamazepine (CBZ) sustained release formulation suitable
for pediatric use with a lower risk of precipitation. The CBZ was first prepared as sustained
release microparticles, and then the microparticles were embedded in alginate beads, and finally, the
beads were suspended in a gel vehicle. The microparticles were prepared by a solvent evaporation
method utilizing ethyl cellulose as a sustained release polymer and were evaluated for particle size,
encapsulation efficiency, and release profile. The beads were fabricated by the dropwise addition of
sodium alginate in calcium chloride solution and characterized for size, shape, and release properties.
The gel was prepared using iota carrageenan as the gelling agent and evaluated for appearance,
syneresis, drug content uniformity, rheology, release profile, and stability. The microparticles exhibited
a particle size of 135.01 ± 0.61 µm with a monodisperse distribution and an encapsulation efficiency of
83.89 ± 3.98%. The beads were monodispersed with an average size of 1.4 ± 0.05 mm and a sphericity
factor of less than 0.05. The gel was prepared using a 1:1 ratio (gel vehicle to beads) and exhibited no
syneresis, good homogeneity, and good shear-thinning properties. The release profile from the beads
and from the gel was not significantly affected, maintaining similarity to the tablet form. The gel
properties were maintained for one month real time stability, but the accelerated stability showed
reduced viscosity and pH with time. In conclusion, CBZ in a gel sustained release dosage form
combines the advantages of the suspension form in terms of dosing flexibility, and the advantages
of the tablet form in regards to the sustained release profile. This dosage form should be further
investigated in vivo in animal models before being considered in clinical trials.
Keywords: gel; sustained release; carbamazepine; epilepsy; pediatric
1. Introduction
Carbamazepine (CBZ) is an epilepsy treatment used by patients of different age groups, including
pediatrics and especially children below six years old. However, the sustained release dosage is only
available as a solid oral dosage form (tablet or capsule). Children below six years old usually have
difficulty swallowing solid oral dosage forms [1–3]. The United States Food and Drug Administration
(FDA) and European Medical Agency (EMA) have encouraged developers to make sustained release
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formulations for pediatric use [4–6]. CBZ can be given as a suspension for children in 2–4 doses per
day, but several side effects have been reported due to precipitation of the suspension [7–9]. This
highlights the need for a new formulation that can provide a sustained release and avoid precipitation
of CBZ. This study aimed to achieve these goals. Making a sustained release formulation suitable for
children with swallowing difficulties (below six years old) is challenging. Based on EMA guidelines,
currently only solution and suspension formulations are suitable for this age group [4–6]. While a
sustained release form is difficult to develop, the suspension dosage form was considered.
Carbamazepine (CBZ) is an anticonvulsant drug used for the treatment of neuralgia, trigeminal,
epilepsy, and bipolar disorder. CBZ is a white-yellowish, bitter tasting powder that is insoluble in
water [10,11]. The FDA approved carbamazepine formulations include chewable tablets (Tegretol®),
a suspension (Tegretol®), sustained release capsules (Carbatrol®), and sustained release tablets
(Tegretol®-XR) [7]. Following a twice a day dosage regimen, the suspension provides higher peak
levels and lower trough levels than those obtained from conventional tablets for the same dosage
regimen. On the other hand, following a thrice daily dosage regimen, the CBZ suspension affords
steady-state plasma levels comparable to CBZ tablets given twice a day when administered at the
same total mg daily dose [7]. Following a twice daily dosage regimen, CBZ extended-release tablets
afford steady-state plasma levels comparable to conventional CBZ tablets given four times a day, when
administered at the same total mg daily dose [7]. CBZ is prescribed for children under 6 years of age at
a dose of 10 to 20 mg/kg/day twice a day or three times a day. The dose is increased weekly to achieve
an optimal clinical response, and administration may be increased to three times a day or four times a
day. As such, the suspension dosage form allows dosing flexibility. However, it lacks the property of
sustained release. This is available only in the solid oral dosage forms, like tablets and capsules. There
is still a need for a sustained release CBZ formulation to be developed that provides both the required
release profile and dosing flexibility.
The International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) has classified five different age groups: preterm new-borns
infants, new-born infants (0–27 days), infants and toddlers (28 days–23 months), children (2–11 years),
and adolescents (12 to 16–18 years, depending on the region) [12,13]. Due to the anatomy of their
buccal cavity development, this young population is usually unable to swallow capsules or tablets.
However, children may be able to swallow small tablets but not larger tablets. According to the
Guideline on Development of Medicines for Paediatric Use, the acceptability of the tablets depends on
their age and the size of the tablets [5,6]. For children from 2 to 5 years old (pre-school), the preferred
dosage forms are solutions and suspensions, with the ability to swallow tablets smaller than 5 mm [5].
However, overdose caused by suspension sedimentation is one of the common reported issues with
CBZ suspensions.
Most of the CBZ sustained release formulations have been developed as tablets. Only a few
formulations have been attempted for paediatric use. Among them, nanoparticles and microparticles are
the most reported, despite the authors not claiming their suitability for the paediatric population [14–20].
However, as multiparticulate systems with a size that can be swallowed by children younger than six
years old, those dosage forms might be useful [21].
There are several types of polymers or coating materials, such as celluloses (like ethyl cellulose,
methyl cellulose, carboxymethyl cellulose), gums (like gum Arabic), carrageenans (kappa carrageenan,
iota carrageenan, and lambda carrageenan), and alginates (sodium alginate). Ethyl cellulose (EC) is
the most stable polymer among the cellulose derivatives. It can resist alkalis in both concentrated and
diluted solutions. It only adsorbs a very small amount of water from the moist air or from aqueous
solutions during immersion [22]. There are three types of carrageenan—kappa carrageenan, iota
carrageenan, and lambda carrageenan. Iota carrageenan is the only type that shows no syneresis [23].
Sodium alginate is a natural polysaccharide polymer that is soluble in cold and hot water. It is
biocompatible, non-toxic, and widely used in pharmaceutical beads, microparticles, nano-particles,
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and sustained release preparations [24]. Beads of alginate are easily prepared by crosslinking with
divalent cations, such as calcium.
Oral gel is a fundamental solution for dysphagic patients and is frequently prescribed for
geriatrics [25,26]. The gel has the advantage of preventing precipitation due high viscosity. In addition,
when the gel is shear-thinned, it allows flexible dosing because it flows easily upon application of
suitable stress, like withdrawal by syringe. Gel formulations have been developed for some drugs
already, such as paracetamol [27]. Gel formulations can be designed for immediate release or sustained
release [28]. One study described a CBZ oral gel and performed a comparison study between different
gelling agents and a stability study for those gelling agents, but the release was almost completed in
1 h (immediate release dosage form) [25,26]. There is no existing report on a sustained release gel
formulation for CBZ.
In this study, a CBZ sustained release formulation suitable for pediatric use, especially for children
below six years old, was developed based on multiparticulate systems (microparticles and beads).
These particles were embedded in a gel as the final dosage form. The in vitro release properties were
compared with those of commercial CBZ sustained release tablets.
2. Materials and Methods
2.1. Materials
Carbamazepine (CBZ) was purchased from Anuja Healthcare Limited (Punjab, India). Ethyl
cellulose (EC) was bought from DOW chemicals (Louisiana, Greensburg, PA, USA). Polyvinyl alcohol
(PVA), dichloromethane, and other chemicals were procured from Merck (Hohenbrunn, Germany).
Sodium alginate was purchased from FMC (Philadelphia, PA, USA). Calcium chloride was obtained
from Merck (Darmstadt, Germany). Iota carrageenan and honey powder were sourced from the
Modernist Pantry (Portsmouth, NH, US). Propyl paraben was bought from Parchem (New Rochelle,
NY, USA).
2.2. Preparation and Characterization of CBZ-Loaded Microparticles
CBZ was encapsulated in ethyl cellulose microspheres using the solvent evaporation technique.
Briefly, 200 mg of CBZ and 200 mg of EC were dissolved in 10 mL dichloromethane to create the oil
phase. The aqueous phase was prepared by dissolving PVA in water at 1% w/v concentration. Ten mL
of the oil phase was added to 30 mL of the aqueous phase (ratio of 1:3) and mixed at 6000 rpm using a
homogenizer for 180 s. The mixture was added to 120 mL of the dispersion medium of distilled water
(ratio 1:3 emulsion to dispersion medium) and stirred for 3 h at room temperature to evaporate the
organic solvent. Microparticles were collected by filtration then washed three times with distilled
water [29,30].
The particle size of the CBZ-loaded microparticles was evaluated by suspending the microparticles
in distilled water, followed by the measurement using a laser diffraction particle sizer (BT-9300H,
Liaoning, China). Polydispersity of the microparticles was evaluated by calculating the span value
(Equation (1)).
Span value = (D90 − D10)/D50, (1)
where D10: 10% of the particles are smaller than this diameter; D50: 50% of the particles are smaller
than this diameter; D90: 90% of the particles are smaller than this diameter [31].
The particle morphology was observed under a light stereomicroscope (Nikon SMZ745, Tokyo,
Japan) attached to a Nikon special lens (Nikon DS-Fi2, Tokyo, Japan).
The presence of CBZ in the microparticles was confirmed by attenuated total reflectance Fourier
transform infrared (ATR-FTIR) spectroscopy. Ethyl cellulose, CBZ, and CBZ microparticles were
scanned in the range 4000–400 cm−1 using a Perkin-Elmer FTIR spectrometer (Perkin Elmer Corp.,
Norwalk, CT, USA).
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The amount of CBZ encapsulated in the microparticles was determined by adding 10 mg of
microparticles into 100 mL phosphate buffer at pH 6.8 and stirring at 200 rpm using an incubator
shaker (INNOVA 4000, GMI, Ramsey, MN, USA) at 37 ± 0.05 ◦C for 4 h. Then, the sample was
filtered (Whatman filter paper grade 1) and analyzed (n = 3) at 286 nm using a UV-spectrophotometer
(SHIMADZU UV-1800, Kyoto, Japan). Encapsulation efficiency was calculated by dividing the actual
amount of CBZ in the microparticles by the theoretical amount.
2.3. Encapsulation of CBZ-Loaded Microparticles in Alginate Beads
A quantity of the microparticles equivalent to 200 mg of CBZ was suspended in 5 mL of 2% w/v
sodium alginate solution using a magnetic stirrer. The electrospray apparatus was assembled using a
high voltage power supply from Genvolt (Shropshire, UK) and a syringe pump from Shenchen Pump
(Baoding, China), and a stainless-steel needle. The microparticle-in-alginate suspension was extruded
into 1% w/v calcium chloride solution using the electrospray at a 1 mL/min flow rate, with a 10 cm
distance between the needle head and calcium chloride solution, and 4000 kV. Alginate beads were
formed instantly by means of crosslinking between the alginate and calcium ions. The beads were
collected using a metal mesh and washed using distilled water.
The particle size of 10 beads was determined using a digital microscope, U500 Shenzhen
(Guangdong, China). The sphericity factor (SF) was used as an indication of the shape of the beads
and calculated using Equation (2).
Sphericity factor (SF) = (Dmax − Dmin)/(Dmax + Dmin), (2)
where Dmax is the longest diameter and Dmin is the shortest diameter of the same bead.
The EE of the CBZ in the alginate beads was measured to ensure the loading of CBZ-loaded
microparticles inside the beads. An indirect method was utilized by measuring the un-encapsulated
amount of CBZ. Un-encapsulated CBZ leaks into calcium chloride solution either as soluble CBZ or
as microparticles. Soluble CBZ was quantified using a spectrophotometer at a 286 nm wavelength.
Meanwhile, measurement at 600 nm was also conducted and used to measure the turbidity in the
calcium chloride solution resulting from the presence of microparticles that have not been embedded
in the beads.
2.4. Loading of CBZ Alginate Beads in a Gel Vehicle
The gel vehicle was prepared by heating 40 mL of distilled water up to 90 ◦C, followed by addition
of the gelling agent under continuous stirring. After complete dissolving and cooling, propyl paraben
sodium was added as preservative then the solution was made up to 50 mL with distilled water. Two
types of carrageenan (iota or kappa) at two concentrations (1 and 2.5% w/v) were used as gelling agents.
CBZ alginate beads containing 2000 mg CBZ (about 50 mL as volume) were added into the gel vehicle
at 40 ◦C, then left to cool down at room temperature to produce the gel formulation. The final gel
formulation was prepared in two ratios—1 to 1 and 1 to 2 volume ratios of beads to iota carrageenan
jelly. Therefore, the volume fraction of the alginate beads in the final gel was 1/2 (for the 1 to 1 ratio)
and 1/3 (for the 1 to 2 ratio).
2.5. Characterization of CBZ Oral Gel
2.5.1. Physical Appearance and Syneresis
Visual observation of the fabricated CBZ-oral gels was undertaken to assess their clarity, smell,
texture, and the presence of any foreign particles. The texture of the prepared gels was tested by
rubbing them between two fingers to check their grittiness and stickiness.
Water separation from the gel is known as syneresis, which is a common problem associated with
jellies during their storage [32–34] (Brinker and Scherer, 2013). Iota and kappa carrageenan gels at two
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different concentrations (1% and 2.5% w/v) were stored at room temperature (25 ± 2 ◦C) and in the
refrigerator (8 ± 3 ◦C) for 24 h to observe syneresis, if any [25].
2.5.2. Homogeneity
A homogeneity test was carried out to ensure the distribution uniformity of CBZ beads in the
gel. Beads prepared from 5 mL alginate suspension were added into 5 mL or 10 mL 2.5% w/v iota
carrageenan gel to yield a ratio of 1:1 or 1:2. Three 1 mL aliquots from the gel (upper, middle and
lower regions) were individually dissolved in 100 mL of phosphate buffer (pH 6.8) under continuous
shaking at 200 rpm using an incubator shaker (Innova 4000, GMI, Ramsey, MN, USA) at 37 for 4 h.
The samples were filtered and analyzed at 286 nm using a spectrophotometer (Shimadzu UV-1800,
Kyoto, Japan) [35].
2.5.3. Rheology
Iota carrageenan gelling agent was first tested for rheology using a HAAKE Mars rheometer
(Thermo-Scientific, Waltham, MA, USA). The data were then digitally analyzed by Haake Rheo-Win
3.61.0000 software (Thermo-Scientific, Waltham, MA, USA). The test was conducted at 25 ◦C ± 0.05 ◦C
using a PP35 Ti spindle of 35 mm diameter and 1 mm gap. The test was conducted at an increasing
shear rate (γ) from 0.01 to 100 s−1 at 1 Hz frequency, then a constant shear rate of 100 s−1 for 30 s, then
a decreasing shear rate from 100 to 0.015 in 120 s [36]. The results were represented graphically as
apparent viscosity (η), and shear stress (τ) vs. shear rate (γ). The same test was repeated after loading
the CBZ alginate beads in the gel vehicle. Rheological modelling for each of the gels was fitted to either
the Herschel Bulkley or Ostwald De Waele model.
2.6. In Vitro Drug Release
The sustained release properties of the CBZ gel formulation were evaluated and compared with
the commercially available 200 mg Tegretol®-XR sustained release tablet (Novartis), by calculating
the similarity factor (F2) using Equation (3). In addition, the release profiles of CBZ powder, CBZ
microparticles, and CBZ-alginate beads were also compared in order to observe the effect of each
preparation step on the release properties.
f2 = 50log

1 + 1ρ
ρ∑
j=1
(
uTj − uRj
)2
− 12
× 100
, (3)
where F2 is the similarity factor, Rt and Tt are the dissolved cumulative percentage of test and reference
samples at selected (t) time points respectively, and n is the number of time points [37–39].
The release profile tests were conducted with a USP-II dissolution apparatus using a 900 mL
volume of dissolution medium at 37 ± 0.5 ◦C and a rotating speed of 100 rpm. At a predetermined
time, point (1, 3, 6, 12, and 24 h), 5 mL of dissolution medium was taken (n = 3) and replaced with an
equal volume of fresh medium. The samples were filtered and analyzed spectrophotometrically at the
wavelength of 286 nm.
For CBZ powder, CBZ microparticles and CBZ-alginate beads, the dissolution test was adopted
from United States Pharmacopeia (USP), since these formulations can be considered solid dosage
forms [40]. However, CBZ gel is a new dosage form not described in USP. Therefore, to compare it
with commercial formulations, the dissolution was conducted using the two stage general dissolution
method (HCl and phosphate buffer stages).
The Tegretol®-XR sustained release tablets containing 200 mg CBZ were immersed in HCl for the
first 2 h, then the disintegrated tablet was filtered using Whatman filter paper no. 1. The tablet particles
were collected easily, then transferred directly into phosphate buffer (pH 6.8) to continue the dissolution
test for up to 24 h. For the CBZ gel, an amount containing 200 mg CBZ was immersed in HCl for 2 h.
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In another dissolution vessel, a similar quantity was added into the phosphate buffer pH 6.8 and the
test was run for 24 h. The readings from 2 h were deducted from all subsequent readings.
2.7. Stability Study
The CBZ gel formulation, packed in glass containers, was evaluated for physical stability at
30 ± 2 ◦C with 70 ± 5% RH (real time stability conditions) and 40 ± 2 ◦C with 70 ± 5% RH (accelerated
stability conditions) for 30 days (Countries, 2005). At different time points (0, 7, 15, and 30 days),
various quality attributes were evaluated, including pH, physical appearance, syneresis, viscosity, and
assay. The viscosity was evaluated using a Brookfield® viscometer (DVII+, Massachusetts, USA) with
a spindle number (CPE51) at room temperature (25 ◦C ± 5 ◦C) and a rotating speed of 50 rpm [32].
2.8. Statistical Analysis
Statistical analysis was completed using a fractional factorial design for the preparation of all
formulations, and a t-test for the stability study of the gel utilizing Minitab software (version 17.1.0;
Minitab Inc., State College, PA, USA). When the p-value is less than 0.05 the null hypothesis will be
rejected, and it will be considered as significant. When p-value is more than 0.05, the results will be
considered as not significant and the null hypothesis will be accepted.
3. Results
3.1. CBZ-Loaded Microparticles
CBZ was successfully encapsulated in ethyl cellulose microparticles using the solvent evaporation
method. The microparticles exhibited a particle size of 135.01 ± 0.61 µm with a monodisperse
distribution (Figure 1), a span value of 1.28, and an encapsulation efficiency (EE) of 83.89 ± 3.98%.
ATR-FTIR spectra confirmed the presence of CBZ in the microparticles, where CBZ peaks were clearly
seen in the microparticle spectrum as presented in Figure 1c.
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diffraction, (b) morphology of the particles under a light icroscope, (c) ATR-FTIR spectra of ethyl
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3.2. CBZ-Loaded Microparticles in Alginate Beads
Alginate beads were formed instantly upon contact of alginate solution containing CBZ-loaded
microparticles with calcium chloride solution. The beads were spherical (Figure 2) with a size
of 1.4 ± 0.05 mm and a sphericity factor of less than 0.05, which is considered spherical [41].
Spectrophotometric measurements revealed that only 0.38 ± 0.01% of the CBZ was un-encapsulated
and dissolved in the calcium chloride solution. No CBZ-loaded microparticles were detected in the
calcium chloride solution, whereby the turbidity of the solution did not change. This reveals that the
encapsulation efficiency of CBZ in the beads was 99.62 ± 0.01%.
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Figure 2. (a) CBZ-alginate beads, (b) CBZ-gel prepared at a :1 rati of beads to iota carrageenan gel.
3.3. CBZ Oral Gel
3.3.1. Physical Appearance and Syneresis
CBZ gel prepared from iota carrageenan were transparent, non-sticky, of acceptable consistency,
and without any feeling of grittiness. No syneresis was seen with any of the iota carrageenan gels, while
all the kappa carrageenan gels exhibited syneresis except for the 2.5% gel stored in the refrigerator.
3.3.2. Homogeneity
Table 1 shows the assay results of CBZ from samples taken from different locations of the gel. The
average value of the three locations was 100%. The ratio of 1:1 shows very close agreement between
the three locations, while in the 1:2 ratio the CBZ was not homogenously distributed. The lower layer
had a high concentration of CBZ compared to the upper layer due to precipitation of the CBZ-alginate
beads in the bottom of the gel container.
Table 1. Homogeneity of CBZ gel.
Sample Location Beads to Gel Ratio CBZ Assay (%)
Up (1:1) 100.9 ± 1.3
Middle (1:1) 99.9 ± 1.1
Bottom (1:1) 99.2 ± 1.9
Up (1:2) 65.4 ± 2.4
Middle (1:2) 96.5 ± 3.3
Bottom (1:2) 138.0 ± 4.5
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3.3.3. Rheology
The rheology profile for 2.5% w/v iota carrageenan gel exhibited a non-Newtonian profile, where
the shear stress increased non-linearly with the shear rate. The gel fits the Herschel Bulkley model
(R = 0.9981) with clear yield shear stress (Figure 3). However, after incorporating CBZ-alginate beads
at a 1:1 loading ratio, the gel did not fit any model and exhibited a degree of thixotropy. The rheology
profile of the gel containing the beads was disrupted with spikes. This was because the bead size was
more than 1 mm and the gap between the upper and lower spindles was 1 mm. When the spindle
rotated, it smashed and compressed the beads. Therefore, the measurement of gel rheology was
interrupted with the presence of beads in the gel. The overall trend represents the gel where it appeared
to have a shear thinning property with a degree of thixotropy, but the spikes in the graph came from
the beads.
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3.4. In vitro Drug Release
CBZ oral gel exhibited a sustained release profile for 24 h (Figure 4). The release was comparable
to the release from co mercial Tegretol®-XR tablets, ith a similarity factor of f 2 = 74. At t50 % the
percentage of CBZ release from the microparticles was 71.05%, was 74.12% from the bea 68.94%
from the gel, and was 68.25% from the commercial Tegretol®-XR tablets. These results revealed that
the prepared CBZ gel was comparable to the commercial tablet.
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Release kinetic fitting is shown in Table 2. CBZ microparticles fitted best into the Higuchi
model, suggesting a diffusion controlled mechanism. This was expected as the polymer used in the
microparticle preparation was ethyl cellulose, which is not a fast degrading polymer. Therefore, the
CBZ will release by diffusing through the microparticle matrix. On the other hand, CBZ beads and CBZ
gel fitted best into first order kinetics. The presence of an alginate matrix around the microparticles,
then the gel around the beads, slowed down the release.
Table 2. Fitting of the release profiles into different kinetic models.
Model R2
CBZ
Microparticles CBZ Beads CBZ Gel
CBZ Tablets
(Tegretol®-XR)
Zero Order 0.7190 0.8828 0.8143 0.8601
First Order 0.8555 0.9968 0.9759 0.9301
Higuchi 0.9222 0.9842 0.9482 0.9591
Korsmeyer Peppas 0.6973 0.7677 0.8121 0.8457
Hixson Crowell 0.8116 0.9760 0.9527 0.9748
3.5. Stability Study
The appearance and texture of the gel in terms of stickiness did not change during the stability
study (Table 3). No syneresis was observed within the stability period. The pH slightly dropped with
time in both real time and accelerated conditions, but the change was not significantly different, with a
p-value of 0.25. Viscosity of the gel stored at 40 ◦C decreased significantly, while no significant change
was observed for the sample stored at 30 ◦C.
Table 3. Stability study of CBZ gel.
Test Initial (0) Days 7 Days 15 Days 30 Days
Real Time Conditions (30 ± 2 ◦C/70 ± 5% RH)
Appearance Transparent withembedded white beads No change No change No change
Syneresis No No No No
pH 5.7 ± 0.0 5.4 ± 0.1 5.1 ± 0.0 4.5 ± 0.5
Viscosity (mPa.s) 644 ± 271 552 ± 239 676 ± 173 899 ± 208
Accelerated Conditions (40 ± 2 ◦C/70 ± 5% RH)
Appearance Transparent withembedded white beads No change No change No change
Syneresis No No No No
pH 5.8 ± 0.1 5.4 ± 0.0 4.6 ± 0.1 5.0 ± 1.8
Viscosity (mPa.s) 357 ± 37 325 ± 5 253 ± 92 180 ± 22
4. Discussion
CBZ was first encapsulated in microparticles using an ethyl cellulose polymer, a well-known
polymer for sustained release formulations [42–46]. The microparticles exhibited good sustained
release properties, comparable to those of commercial tablets that are given twice daily. However,
CBZ-loaded microparticles precipitate when suspended in a liquid vehicle. In addition, microparticles,
as relatively large particles, give an unpleasant gritty feeling.
To overcome the precipitation issue of the microparticles, gel was proposed as a vehicle for the
microparticles. Gels have high viscosity and do not flow in the normal conditions of temperature and
stress, so precipitation is avoided. However, the grittiness of the microparticles may not be overcome.
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In addition, CBZ may slowly leak out from the microparticles into the gel during long-term storage,
resulting in loss of the sustained release properties. To solve this issue, another layer of coating was
considered, using alginate beads. Upon crosslinking of alginate with calcium ions, rubbery gel beads
are formed with no gritty texture. Alginate beads were prepared to encapsulate the CBZ-loaded
microparticles. The beads were spherical in shape, within the recommended size for pediatric use
(1–6 years old), and effectively entrapped the microparticles inside them. Since the targeted sustained
release profile was obtained from the microparticles, the beads should have little effect on the release
profile. The required or the target release profile was found to be similar to the release profile of
commercial sustained release tablets, as stated in the United States Pharmacopeia (USP39)—10–35% in
3 h, 35–65% in 6 h, 65–90% in 12 h, and not less than (NLT) 75% in 24 h [47]. A kinetic release study
showed that the all prepared formulations followed first order release mechanisms, as the coefficient
correlation (R2) was equal to 0.989 for the CBZ microparticles, 0.976 for the CBZ beads, 0.948 for the
CBZ gel, and 0.948 for the Tegretol®-XR tablets. The first order model explained that the release of CBZ
based on its dosage form was CBZ-concentration dependent. This means that the release of the drug
can be increased when the concentration of that drug is increased in the dosage form over time [48–50].
The release study confirmed that the release of CBZ from the beads was comparable to that of the
microparticles and was still similar to that of the commercial tablet.
The last step was to suspend the beads in the gel vehicle. This was performed at a temperature
slightly higher than the solidifying temperature of the gelling agent. In comparing kappa and
iota carrageenan at two concentrations, iota carrageenan gave the needed properties: no syneresis,
homogenous, and with shear-thinning properties. During gel preparation the beads tended to
precipitate due to the low viscosity of the hot gel. This is why homogeneity was better at a higher
concentration of the beads, where the gel amount was just enough to suspend the beads. The
shear-thinning property is needed for this medicated gel in order to allow easy dispensing. Iota
carrageenan gel fits the Herschel-Bulkley model, which means it has yield stress—the state of the gel
does not change until a specific stress is applied. The gel has high viscosity during storage to prevent
bead precipitation, but the viscosity decreases upon applying stress like syringe withdrawal. This allows
flexible dosing based on body weight, like a normal CBZ suspension. Similar to the beads, the iota
carrageenan gel vehicle was found to have no significant effect on the release properties of CBZ-loaded
microparticles. Consequently, the sustained release profile from the final formulation (CBZ-loaded
microparticles-in-beads-in-gel) was similar to that of the FDA-approved Tegretol®-XR tablet.
The physical stability study showed that the gel formulation maintained its properties for 30 days
when stored at 30 ◦C. However, the gel viscosity decreased when it was stored at 40 ◦C. This highlights
the importance of storage conditions for this formulation. The pH of the gel was slightly acidic after
preparation and showed a decreasing trend during the stability period. Using an ANOVA as the
statistical analysis, the change in pH value was found to be not significant, possibly due to the large
standard deviation of some points. The change in pH might be attributed to the fact that carrageenans
are susceptible to acid-catalyzed hydrolysis [51]. Since the gel was slightly acidic after preparation,
the hydrolysis of iota carrageenan might occur and accelerate at a higher temperature, leading to
a further drop in pH. This explains the faster drop in pH under the accelerated stability condition
(40 ◦C) compared to the real-time condition (30 ◦C). Such a change in pH is important to avoid. Iota
carrageenan undergoes rapid and extensive loss of viscosity and gelation potential when solutions
below pH 5 are heated. The loss of viscosity and gelation potential is primarily due to cleavage of the
(1→3) glycosidic linkages [51]. For the gel dosage form, viscosity is critical and should be maintained.
The pH of the formulation can be controlled by adding suitable buffering systems.
Based on these preliminary results of the stability study, the gel might need to be stored in the
fridge (5 ± 3 ◦C). A scale up study is recommended to ensure suitability of the preparation method for
large scale production. Further investigations are needed, but they are recommended to be done for a
larger scale preparation.
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5. Conclusions
A carbamazepine sustained release new dosage form designed for pediatric use was prepared
and analyzed in this study. This dosage form was based on encapsulation of carbamazepine in
microparticles to obtain the required sustained release profile. The microparticles were then embedded
in alginate beads, which, in turn, were suspended in iota carrageenan gel. The developed formulation
has the advantages of a suspension formulation, that is, flexible dosing and being easy to swallow. It
also overcomes the issue of carbamazepine precipitation that is seen in the suspension formulation,
which leads to overdose. Carbamazepine sustained release gel has the potential to make the advantages
of a sustained release dosage form to pediatric patients accessible, especially children below six years
old who have no current option for such a formulation.
6. Patents
The gel as dosage form was patented under the file number (PI 2017704458/Malaysia), under the
patent name “A sustained-release drug composition”.
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